Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan